Regenerative Biologics
in Oral & Maxillofacial
Surgery

Sinus augmentation is required when posterior maxillary bone height falls below the 8–10 mm threshold needed for implant primary stability — a common finding after long-term maxillary molar loss, where the sinus pneumatizes downward while the alveolar ridge resorbs. The lateral window approach (Tatum technique) generates the largest bone volume augmentation; the transcrestal approach (Summer’s osteotome technique) is applicable when ≥4–5 mm of residual bone height is present and 3–4 mm of elevation is sufficient.

DBM particulate — either DFDBA alone or mixed with autologous bone chips and PRP — is the most evidence-supported graft material for sinus augmentation, matching the clinical outcomes of iliac crest autograft without the donor site morbidity. Amniotic membrane covering a Schneiderian membrane perforation converts a case-abandonment scenario into a manageable complication, with 95.8% graft survival in published series when perforations ≤5 mm are covered with lyophilized amniotic membrane before graft placement.

Periodontal osseous defects — intrabony defects, furcation defects, and dehiscence defects adjacent to teeth — result from periodontitis-driven bone resorption and represent the target for periodontal regeneration procedures. The biological goal of regeneration (restoration of PDL-cementum-bone complex) is distinct from repair (new bone filling the defect without periodontal attachment). DFDBA, EMD, and rhPDGF-BB each address specific aspects of this regenerative cascade.

The highest-level evidence protocol for intrabony defects combines guided tissue regeneration (resorbable membrane) with DFDBA and, where available, EMD or rhPDGF-BB. Meta-analytic data shows 3–4 mm greater probing depth reduction and 2–3 mm greater bone fill with biologics vs. open flap debridement alone. For Class II furcation defects, DFDBA combined with GTR membrane shows significantly better furcation closure rates than either alone — the furcation geometry making biologic support of the complex three-dimensional regeneration particularly important.

Guided bone regeneration for horizontal and vertical ridge defects uses barrier membranes (resorbable or non-resorbable) to exclude the rapidly proliferating soft-tissue cells from the regeneration space, allowing the slower-growing osteoprogenitor cells to fill the defect with bone. Biologic augmentation within the GBR space addresses the rate-limiting step: inadequate growth factor and progenitor cell supply within the protected space.

DBM particulate under Ti-mesh or e-PTFE membrane for vertical ridge augmentation is the standard protocol for large defects (>3 mm vertical). PRP mixed with the graft accelerates early revascularization of the avascular graft particles from the residual bone walls. BMAC addition is considered for defects in compromised patients (diabetes, smoking, prior radiation) where osteoprogenitor quality or density is reduced. The consistent finding across GBR biologic trials: biologics accelerate the maturation timeline and improve bone density within the regenerated volume — supporting earlier implant placement and better osseointegration.

Medication-related osteonecrosis of the jaw (MRONJ) — formerly BRONJ (bisphosphonate-related) — occurs in patients on antiresorptive (bisphosphonates, denosumab) or antiangiogenic therapies, presenting as exposed, necrotic bone in the jaw unresponsive to standard care for ≥8 weeks. The fundamental biology is impaired angiogenesis and osteoprogenitor function: bisphosphonates suppress osteoclast activity (reducing bone remodeling) while also impairing endothelial progenitor function (reducing neovascularization of healing sites).

BMAC provides the most mechanistically targeted biologic intervention for MRONJ — delivering VEGF-A and Ang-1 for angiogenic support of the hypovascular post-bisphosphonate bone, MSC osteoprogenitors to replace the suppressed osteoclast-osteoblast coupling, and IL-10 and TSG-6 for anti-inflammatory support of the chronically infected necrotic site. Prospective data (Mücke 2017) shows 83% complete mucosal closure with BMAC-augmented surgical debridement vs. 40–60% with debridement alone — a clinically meaningful improvement for a condition with very limited effective treatment options.

The temporomandibular joint is a diarthrodial synovial joint subject to the same OA pathophysiology documented in the appendicular joints — IL-1β-driven cartilage degradation, synovial inflammation, subchondral bone changes — with the additional challenge of continuous masticatory loading and the proximity of the joint to the middle cranial fossa, parotid gland, and facial nerve. TMJ OA and internal derangement are highly prevalent conditions with limited conventional treatment options beyond splint therapy, NSAIDs, and arthrocentesis.

Intra-articular PRP for TMJ internal derangement and early OA has been evaluated in multiple prospective series and comparative trials. The mechanism mirrors peripheral joint OA treatment: PDGF-BB and TGF-β1 stimulate synoviocyte and chondrocyte matrix synthesis; IL-1β inhibition via α2-macroglobulin reduces cartilage catabolism; VEGF promotes synovial vascularity. Comparative data vs. hyaluronic acid shows equivalent or superior VAS and MIO (maximum interincisal opening) improvement at 6–12 months — consistent with the pattern observed in other joint OA PRP comparisons.

Gingival recession — the apical migration of the gingival margin exposing tooth root surfaces — affects 50–88% of adults and is associated with root sensitivity, aesthetic concerns, and progressive tooth loss risk. The standard surgical treatment (subepithelial connective tissue graft — SCTG) requires palatal donor tissue harvest with associated morbidity. Lyophilized collagen matrix and amniotic membrane-derived products are being evaluated as donor site substitutes.

PRP combined with coronally advanced flap surgery for recession coverage has been evaluated in multiple RCTs, showing superior root coverage percentage (+8–12% mean root coverage improvement) and faster mucosal healing vs. flap surgery alone. The EGF and KGF content of PRP drives keratinocyte migration over the exposed root surface, while PDGF-BB promotes connective tissue fibroblast proliferation and attachment fiber formation. Amniotic membrane as a subepithelial connective tissue substitute — without requiring palatal harvest — shows comparable recession coverage at 6 months in prospective comparative series.

Large mandibular defects from trauma, tumor resection, or avascular necrosis require bone regeneration that exceeds the capacity of standard bone grafting. Vascularized free flap reconstruction (fibula free flap) remains the gold standard for defects >6 cm; biologics augment the reconstruction environment and are primary treatment for smaller defects or patients not fit for free flap surgery.

BMAC mixed with DBM in titanium mesh-protected defects can predictably regenerate mandibular continuity defects up to 4–5 cm in staged protocols — the BMAC providing autologous MSC osteoprogenitors and growth factor support to the osteoinductive DBM scaffold within a mechanically protected space. Distraction osteogenesis augmented with BMAC injection at the consolidation phase reduces total treatment time by 25–35% in prospective series, by accelerating callus mineralization and cortical maturation.